医学
析因分析
2型糖尿病
基线(sea)
糖尿病
事后
内科学
内分泌学
海洋学
地质学
作者
Christophe De Block,Jennifer Peleshok,John Wilding,Anita Y. M. Kwan,Neda Rasouli,Juan M. Maldonado,Carol Wysham,Minzhi Liu,Grazia Aleppo,Brian D. Benneyworth
标识
DOI:10.1007/s13300-024-01660-0
摘要
Newer incretin-based therapies for type 2 diabetes (T2D) have the potential to substantially reduce glycated hemoglobin (HbA1c) and weight with a low associated risk of hypoglycemia. This study aimed to assess the percentage of participants randomized to tirzepatide or comparator who achieved the composite endpoint of HbA1c ≤ 6.5% and weight reduction ≥ 10% without hypoglycemia across prespecified baseline characteristics: T2D duration (≤ 5, > 5-10, or > 10 years), sex, HbA1c (≤ 8.5% or > 8.5%), age (< 65 or ≥ 65 years), and body mass index (< 30, 30 to < 35, or ≥ 35 kg/m
科研通智能强力驱动
Strongly Powered by AbleSci AI